DENTSPLY SIRONA Inc
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
XRAY$9.70+1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(in millions)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income | $19 | $17 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Depreciation | 34 | 32 |
| Amortization of intangible assets | 45 | 54 |
| Indefinite-lived intangible asset impairment | — | 6 |
| Deferred income taxes | 1 | (9) |
| Stock-based compensation expense | 10 | 11 |
| Other non-cash expense | 9 | 19 |
| Changes in operating assets and liabilities: | ||
| Accounts and notes receivable-trade, net | (31) | 27 |
| Inventories, net | (26) | (5) |
| Prepaid expenses and other current assets | (1) | (28) |
| Other noncurrent assets | 4 | (6) |
| Accounts payable | 14 | (28) |
| Accrued liabilities | (44) | (50) |
| Income taxes | (12) | (2) |
| Other noncurrent liabilities | (15) | (13) |
| Net cash provided by operating activities | 7 | 25 |
| Cash flows from investing activities: | ||
| Capital expenditures | (19) | (34) |
| Cash received on derivative contracts | 1 | — |
| Cash paid on derivative contracts | — | (9) |
| Proceeds from sale of property, plant, and equipment | 1 | — |
| Net cash used in investing activities | (17) | (43) |
| Cash flows from financing activities: | ||
| (Repayments) proceeds on short-term borrowings, net | (272) | 23 |
| Proceeds from 364-day bridge loan | 435 | — |
| Cash dividends paid | (32) | (29) |
| Repayments on long-term borrowings | (2) | (3) |
| Cash paid for deferred financing costs | (3) | — |
| Other financing activities, net | (3) | (5) |
| Net cash provided by (used in) financing activities | 123 | (14) |
| Effect of exchange rate changes on cash and cash equivalents | 13 | (11) |
| Net increase (decrease) in cash and cash equivalents | 126 | (43) |
| Cash and cash equivalents at beginning of period | 272 | 334 |
| Cash and cash equivalents at end of period | $398 | $291 |
| Supplemental disclosures of cash flow information: | ||
| Interest paid, net of amounts capitalized | $13 | $15 |
| Non-cash investing activities: | ||
| Property, plant and equipment in accounts payable at end of period | $22 | $24 |
| Exchange of inventory for naming and other rights | $14 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.